{"classes":[{"categories":[{"measurements":[{"comment":"Too few events occurred to estimate a median and confidence interval.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 25 mg lenalidomide PO daily on days 1-21 and 40 mg dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive 200 mg pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.","id":"OG000","title":"Treatment (Lenalidomide, Dexamethasone, Pembrolizumab)"}],"paramType":"MEDIAN","populationDescription":"All patients that began protocol treatment are included in this analysis.","reportingStatus":"POSTED","timeFrame":"From time of registration to death due to any cause, assessed up to 3 years","title":"Survival Time","type":"SECONDARY","unitOfMeasure":"months"}